Inspire Medical Systems Earnings Call Transcripts
Fiscal Year 2026
-
Leadership highlighted ongoing profitable growth, strategic investments, and efficient operations. Recent reimbursement changes, including new C-codes and the WISeR program, are being managed, with a long-term CPT code solution in progress. Inspire V’s strong clinical data, innovation, and platform upgrades support continued market leadership despite new competition.
-
Inspire V's full launch drove strong Q4 results and improved margins, with 2025 revenue guidance at $912 million and 2026 growth projected at 10%-11%. Product innovation, digital tools, and direct-to-consumer efforts are expanding market reach, while reimbursement clarification and new clinical data support future growth.
Fiscal Year 2025
-
Q4 and full year 2025 saw double-digit revenue growth, improved margins, and strong cash flow, but 2026 guidance reflects significant reimbursement uncertainty due to coding changes. Inspire V adoption is high, with robust clinical outcomes, and the company is pursuing both short- and long-term solutions to reimbursement challenges.
-
Strong Q3 results and reaffirmed guidance set the stage for a robust Q4, with Gen V transition nearly complete and reimbursement increases poised to boost both hospital and commercial rates. Gen V adoption is driving higher volumes and efficiency, while new product and pipeline innovations target expanded patient populations.
-
Inspire 5's successful rollout drove improved outcomes, operational efficiency, and margin gains, with most centers transitioned and strong patient demand. Growth is supported by DTC campaigns, ASC expansion, and a robust innovation pipeline, while clinical data strengthens payer support.
-
Q3 2025 revenue grew 10% year-over-year to $224.5M, driven by Inspire V adoption and strong clinical outcomes. Full-year revenue guidance is reaffirmed at $900-$910M, with EPS guidance raised to $0.90-$1. GLP-1s and reimbursement changes are expanding the patient pool and supporting growth.
-
Surgeon training and account readiness for Inspire V are nearly complete, with full adoption targeted by year-end. Guidance was reduced due to patient warehousing and inventory destocking, but growth is expected to accelerate in 2025 as Inspire V adoption expands and new data supports its benefits.
-
Q2 2025 revenue grew 11% year-over-year, but full-year guidance was reduced due to delays in the Inspire V rollout and related headwinds. Gross margin remained strong at 84%, and early clinical data for Inspire V is promising. Revenue growth is expected to accelerate in 2026 as transition challenges are resolved.
-
Inspire V's launch brings a streamlined implant procedure, improved patient outcomes, and enhanced therapy adherence. Surgeons are adopting the device rapidly, with operational efficiencies expected to drive growth and profitability, even as $10–$15 million in revenue shifts to later quarters.
-
Inspire V's launch introduces faster, more precise therapy with integrated sensing and streamlined procedures, receiving strong clinical and surgeon feedback. Ongoing studies and a robust pipeline support continued growth, while operational efficiencies offset lower surgeon fees.
-
Inspire 5 has officially launched, simplifying procedures and reducing surgical time, with a smooth transition expected as centers update contracts and train staff. Q2 is a transition quarter, but growth and margin improvements are anticipated in the second half of the year, supported by increased marketing and operational efficiencies.
-
Q1 revenue grew 23% year-over-year to $201.3M, with net income of $3M and strong U.S. growth. Full-year guidance is reiterated, with Inspire 5's full U.S. launch expected to drive a strong H2 after a transitionary Q2. Gross margin remains robust at 84.7%.
-
Management reaffirmed 2025 revenue guidance and expects a strong year, with Inspire V’s full launch planned by year-end. Operational improvements, digital tools, and a shift in reporting metrics support growth, while feedback on Inspire V is highly positive.
-
Strong 2024 results with $803M revenue and first full year of profitability set the stage for 17–19% growth in 2025, driven by the FDA-approved Inspire V system. Operational and leadership changes support scaling, while clinical outcomes and patient satisfaction remain high.
Fiscal Year 2024
-
Achieved record revenue and first full year of profitability in 2024, driven by strong US and international growth, successful Inspire 5 device launch, and operational efficiencies. 2025 guidance projects continued double-digit growth and margin expansion, with ongoing investments in innovation and commercial scale.
-
Q4 guidance reflects regional disruptions, but 2025 revenue and profitability outlooks remain strong, supported by the upcoming Inspire V launch. Operational efficiencies, streamlined clinical processes, and expanded provider training are expected to drive growth, with no price increase but improved margins.
-
The session highlighted ongoing growth in the sleep apnea market, with low current penetration and years of expansion ahead. Inspire 5's launch will reduce procedure time and improve outcomes, while future upgrades and dual-channel devices aim to broaden the addressable market. Operational leverage and digital tools are driving profitability and capacity improvements.
-
Profitability was achieved, with growth now focused on operational efficiency, capacity expansion, and leveraging new technologies and payer policies. Inspire V and medical education are expected to drive adoption, while GLP-1 drugs and smart devices expand the patient funnel. U.S. market remains the priority, with international growth accelerating.
-
Q3 2024 revenue grew 33% year-over-year to $203.2 million, with net income of $18.5 million and strong gross margin. 2024 guidance was raised, reflecting robust US and international growth, new product launches, and resilience despite hurricane and IV saline headwinds.
-
Second half 2024 guidance remains unchanged, with strong commercial expansion and a focus on operational readiness for Inspire V’s full launch in early 2025. GLP-1 therapies and new diagnostic pathways are expected to expand the patient pool, while competition is not anticipated until 2025.
-
Sequential utilization growth and strong patient demand are driving expansion, with 81 new centers added and high productivity at top sites. GLP-1 drugs are expanding patient eligibility, while policy changes and the upcoming Inspire V launch support future growth. Profitability is improving through revenue growth and operational efficiencies.
-
Q2 2024 revenue grew 30% year-over-year to $195.9 million, with net income of $9.8 million and gross margin at 84.8%. Full-year guidance was raised, a $150 million share repurchase was announced, and key regulatory milestones were achieved, including FDA approval for Inspire V.
-
Q1 saw 28% U.S. growth, raised annual guidance, and projected first full-year profitability, driven by strong patient demand and expanding community-based care. Utilization reporting will end in 2025, with new metrics under development, while Inspire V and the PREDICTOR study are set to boost future capacity and efficiency.
-
Therapy outcomes and fundamentals remain strong, with significant market opportunity and robust growth driven by expanding distribution, technology advancements, and operational efficiencies. Full-year profitability is now expected in 2024, supported by high gross margins and increasing utilization.